Filing Details

Accession Number:
0001562180-17-003955
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-12-19 21:05:10
Reporting Period:
2017-12-16
Accepted Time:
2017-12-19 21:05:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1100412 Array Biopharma Inc ARRY Pharmaceutical Preparations (2834) 841460811
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1454001 Ron Squarer C/O Array Biopharma Inc.
3200 Walnut Street
Boulder CO 80301
Ceo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-12-16 23,437 $0.00 139,120 No 4 M Direct
Common Stock Disposition 2017-12-16 10,917 $10.92 128,203 No 4 F Direct
Common Stock Acquisiton 2017-12-18 226,874 $7.30 355,077 No 4 M Direct
Common Stock Acquisiton 2017-12-18 16,835 $5.94 371,912 No 4 M Direct
Common Stock Acquisiton 2017-12-18 110,800 $3.61 482,712 No 4 M Direct
Common Stock Disposition 2017-12-18 273,438 $10.73 209,274 No 4 S Direct
Common Stock Acquisiton 2017-12-19 133,380 $3.61 342,654 No 4 M Direct
Common Stock Acquisiton 2017-12-19 79,688 $4.63 422,342 No 4 M Direct
Common Stock Acquisiton 2017-12-19 333,165 $5.94 755,507 No 4 M Direct
Common Stock Disposition 2017-12-19 546,233 $10.93 209,274 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2017-12-16 23,437 $0.00 23,437 $0.00
Common Stock Restricted Stock Units Acquisiton 2017-12-16 100,000 $0.00 100,000 $0.00
Common Stock Stock Option (Right to Buy) Acquisiton 2017-12-16 600,000 $0.00 600,000 $10.92
Common Stock Stock Option (Right to Buy) Disposition 2017-12-18 226,874 $0.00 226,874 $7.30
Common Stock Stock Option (Right to Buy) Disposition 2017-12-18 16,835 $0.00 16,835 $5.94
Common Stock Stock Option (Right to Buy) Disposition 2017-12-18 110,800 $0.00 110,800 $3.61
Common Stock Stock Option (Right to Buy) Disposition 2017-12-19 133,380 $0.00 133,380 $3.61
Common Stock Stock Option (Right to Buy) Disposition 2017-12-19 79,688 $0.00 79,688 $4.63
Common Stock Stock Option (Right to Buy) Disposition 2017-12-19 333,165 $0.00 333,165 $5.94
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
70,313 2020-12-16 No 4 M Direct
100,000 2021-12-17 No 4 A Direct
600,000 2027-12-16 No 4 A Direct
226,876 2025-04-01 No 4 M Direct
0 2017-05-03 2023-05-03 No 4 M Direct
0 2022-04-26 No 4 M Direct
755,820 2022-04-26 No 4 M Direct
345,312 2024-04-01 No 4 M Direct
0 2023-05-03 No 4 M Direct
Footnotes
  1. Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by the Issuer on December 27, 2016 as a result of the vesting of one fourth of such RSUs.
  2. The option vests in four equal annual installments beginning on December 16, 2018.
  3. The option vests in four equal annual installments beginning on April 1, 2016.
  4. The option vested in four equal annual installments beginning on April 26, 2013.
  5. The option vests in four equal annual installments beginning on April 1, 2015.
  6. The option vested in four equal annual installments beginning on May 3, 2014.
  7. Includes 37,812 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs.
  8. Represents shares withheld to satisfy tax withholding obligations of the reporting person.
  9. Includes 37,812 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs.
  10. These trades were made pursuant to a Rule 10b5-1 trading plan.
  11. The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request.
  12. The RSUs vested on December 16, 2017.
  13. Consists of remaining unvested RSUs awarded to the reporting person for no additional cash consideration on December 16, 2016, which vest in three equal remaining installments beginning December 16, 2018, and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The grant of these RSUs were previously reported on a Table II of a form 4 filed by the reporting person.
  14. Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on December 16, 2018.